Key Findings
Wolfgang Wienand, CEO of Lonza, announced robust growth for the company in the first half of 2026, underscoring the accelerated momentum of its Contract Development and Manufacturing Organization (CDMO) strategy. This growth is driven by expanded long-term collaboration agreements with leading U.S. biopharmaceutical companies for the manufacturing of clinical and commercial biologics, alongside a strategic decision to enhance manufacturing capabilities for antibody-drug conjugates (ADCs) and high-value small molecule therapeutics.
Technical / Clinical Details
Leveraging its strengths as a CDMO, Lonza has broadened its partnerships with major biopharmaceutical companies for the manufacturing of clinical and commercial biologics across a wide portfolio, including antibodies, gene therapies, and cell therapies. This addresses the increasing demand for complex biologics and accelerates customer product development. Furthermore, Lonza has committed to significant manufacturing capacity expansions:
- Dedicated Commercial-Scale Sterile ADC Manufacturing Facility: ADCs, due to their potent cytotoxic payloads and the need for precise conjugation to antibodies, require highly specialized manufacturing facilities. Lonza is expanding its capacity in this area to reinforce its leadership.
- Expansion of Large-Scale Multi-Purpose Sterile Drug Product Facility: Originally designed for biologics, this facility will now also accommodate the sterile manufacturing of high-value small molecule therapeutics. This enables Lonza to support a more diverse range of products, including emerging small molecule modalities such as targeted protein degraders (TPDs).
These expansions solidify Lonza’s position as a ‘one-stop shop’ capable of supporting diverse therapeutic modalities (biologics, ADCs, high-value small molecules). By maintaining advanced technological capabilities and stringent quality standards, Lonza aims to reduce manufacturing lead times and increase overall production capacity.
Background & Context
The pharmaceutical industry is increasingly relying on CDMOs due to the emergence of new therapeutic modalities and the growing complexity of development and manufacturing processes. Biologics, ADCs, and innovative small molecules (like TPDs) require specialized expertise and equipment, prompting many pharmaceutical companies to outsource their manufacturing to expert partners. In this context, integrated CDMOs like Lonza gain a competitive edge by offering services across multiple modalities. This investment by Lonza is a strategic move to respond quickly to evolving market demands and capture future growth opportunities.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments